MX367286B - Composiciones de dexmedetomidina intranasal y sus metodos de uso. - Google Patents

Composiciones de dexmedetomidina intranasal y sus metodos de uso.

Info

Publication number
MX367286B
MX367286B MX2014006961A MX2014006961A MX367286B MX 367286 B MX367286 B MX 367286B MX 2014006961 A MX2014006961 A MX 2014006961A MX 2014006961 A MX2014006961 A MX 2014006961A MX 367286 B MX367286 B MX 367286B
Authority
MX
Mexico
Prior art keywords
methods
dexmedetomidine compositions
intranasal dexmedetomidine
intranasal
compositions
Prior art date
Application number
MX2014006961A
Other languages
English (en)
Spanish (es)
Other versions
MX2014006961A (es
Inventor
A Henwood Geraldine
J Mack Randall
Joseph Koleng John Jr
T Sharr Christopher
Alexander Freyer Charles
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367286(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of MX2014006961A publication Critical patent/MX2014006961A/es
Publication of MX367286B publication Critical patent/MX367286B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014006961A 2011-12-11 2012-12-11 Composiciones de dexmedetomidina intranasal y sus metodos de uso. MX367286B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569255P 2011-12-11 2011-12-11
PCT/US2012/068988 WO2013090278A2 (en) 2011-12-11 2012-12-11 Intranasal dexmedetomidine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2014006961A MX2014006961A (es) 2014-09-22
MX367286B true MX367286B (es) 2019-08-13

Family

ID=48613351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006961A MX367286B (es) 2011-12-11 2012-12-11 Composiciones de dexmedetomidina intranasal y sus metodos de uso.

Country Status (20)

Country Link
US (2) US9795559B2 (enExample)
EP (2) EP2787970B1 (enExample)
JP (2) JP6268100B2 (enExample)
KR (1) KR102190009B1 (enExample)
CN (1) CN104470516A (enExample)
AU (2) AU2012352528B9 (enExample)
BR (1) BR112014019171A8 (enExample)
CA (1) CA2858721C (enExample)
CL (1) CL2014001515A1 (enExample)
CO (1) CO7000773A2 (enExample)
CR (1) CR20140318A (enExample)
DO (1) DOP2014000123A (enExample)
EC (1) ECSP14007644A (enExample)
IL (1) IL232977B (enExample)
MX (1) MX367286B (enExample)
PE (1) PE20142314A1 (enExample)
PH (1) PH12014501273A1 (enExample)
RU (1) RU2692245C2 (enExample)
SG (2) SG11201403094TA (enExample)
WO (1) WO2013090278A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012031720A2 (pt) 2010-06-16 2016-12-06 Cargill Inc composições a base de amido para substituição por látex
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
EP3049059B1 (en) * 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20190060007A (ko) 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2020259440A1 (zh) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
WO2022147537A1 (en) * 2021-01-04 2022-07-07 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens
CN118217243A (zh) * 2021-03-29 2024-06-21 四川普锐特药业有限公司 一种增效防腐且兼顾低刺激性的右美托咪定鼻喷剂
CN113876776A (zh) * 2021-11-04 2022-01-04 江苏大学附属医院 一种复方鼻喷镇痛药剂及其制备方法
US20240207285A1 (en) * 2022-12-20 2024-06-27 Melt Pharmaceuticals, Inc. Midazolam and ketamine for enhanced sedation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025176701A1 (en) * 2024-02-19 2025-08-28 Rigshospitalet Novel pediatric composition of nasal dexmedetomidine
WO2026163107A1 (en) 2025-01-30 2026-08-06 Abusarah, Inc. System and method for administration of a substance

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE69127756T2 (de) 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5713907A (en) 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
NZ332968A (en) 1996-05-29 2000-08-25 Bioxid Oy A controllably dissolvable silica-xerogel prepared via sol-gel
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
AU1319200A (en) 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6582457B2 (en) 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
WO2002089794A1 (en) 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
PT1986642E (pt) 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
WO2008003093A2 (en) 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Pharmaceutical compositions and related methods of treatment
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN101057830A (zh) 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法
BRPI0821647A2 (pt) 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
DK2459183T3 (en) 2009-07-27 2016-01-18 Nocicepta Llc Methods for the treatment of pain
US20130072532A1 (en) * 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof

Also Published As

Publication number Publication date
IL232977A0 (en) 2014-07-31
US20180055764A1 (en) 2018-03-01
CN104470516A (zh) 2015-03-25
CL2014001515A1 (es) 2014-12-05
CA2858721C (en) 2021-03-16
WO2013090278A3 (en) 2014-12-24
ECSP14007644A (es) 2015-11-30
NZ626999A (en) 2016-07-29
EP2787970A2 (en) 2014-10-15
PE20142314A1 (es) 2015-01-23
JP2015513309A (ja) 2015-05-07
BR112014019171A8 (pt) 2017-07-11
AU2018200591A1 (en) 2018-02-15
RU2692245C2 (ru) 2019-06-24
SG11201403094TA (en) 2014-10-30
EP3406247A1 (en) 2018-11-28
JP6505177B2 (ja) 2019-04-24
US9795559B2 (en) 2017-10-24
KR20140107329A (ko) 2014-09-04
HK1203049A1 (en) 2015-10-16
WO2013090278A2 (en) 2013-06-20
AU2012352528B2 (en) 2017-10-26
DOP2014000123A (es) 2014-12-31
EP2787970A4 (en) 2015-10-28
AU2012352528A1 (en) 2014-07-10
IL232977B (en) 2019-01-31
SG10201604653TA (en) 2016-07-28
US10682311B2 (en) 2020-06-16
US20130178465A1 (en) 2013-07-11
CA2858721A1 (en) 2013-06-20
AU2018200591B2 (en) 2018-11-29
CR20140318A (es) 2014-10-28
BR112014019171A2 (enExample) 2017-06-20
AU2012352528B9 (en) 2017-11-02
MX2014006961A (es) 2014-09-22
RU2014128343A (ru) 2016-01-27
EP2787970B1 (en) 2018-04-11
JP6268100B2 (ja) 2018-01-24
KR102190009B1 (ko) 2020-12-15
PH12014501273A1 (en) 2014-09-08
JP2018030850A (ja) 2018-03-01
CO7000773A2 (es) 2014-07-21

Similar Documents

Publication Publication Date Title
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
IN2014DN10670A (enExample)
PH12013501148B1 (en) Metal salt compositions
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
IN2015DN00127A (enExample)
MX339584B (es) Inhibidores de pi3 cinasa y usos de los mismos.
PH12013500065A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
PH12014500904B1 (en) Antibody formulations and methods
MX2013012184A (es) Composiciones formadoras de gel in situ.
JO3755B1 (ar) تركيبات تستوستيرون
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
HK1200314A1 (en) R(+)-n-methyl-propargyl-aminoindan
IL227626A0 (en) A compound of 17-il and γ-ifn inhibitors, preparations containing them and their uses
PL2768936T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
HK1200313A1 (en) Rasagiline citramide
IN2014DN10669A (enExample)
MY165088A (en) Pharmaceutical compositions comprising alisporivir
WO2012139074A3 (en) Migrastatins and uses thereof
WO2012174164A3 (en) Agonists of gpr131 and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration